ASH 2020

ASH 2020

ViPOR Yields Complete Response in Patients with R/R B-Cell NHL

In a phase 1b/2 study of patients with relapsed/refractory B-cell non-Hodgkin's lymphoma, the ViPOR regimen led to complete responses, with no unexpected toxicities.

Oncology Learning Network
What plasma short-chain fatty acids are predictors of response to GvHD therapy?

Holtan describes the results of a clinical trial evaluating how acute GvHD treatment response relates to plasma levels of short-chain fatty acids.

ASH 2020: Highlights for GvHD

GvHD Hub Chair Mohamad Mohty, Hôpital Saint-Antoine and Sorbonne University, Paris, FR, provides the highlights for GvHD from the 62nd ASH Annual Meeting and Exposition.


Alfred Garfall: Evaluating Teclistamab in Relapsed and/or Refractory Multiple Myeloma

Dr. Alfred Garfall discusses evaluating teclistamab in relapsed and/or refractory multiple myeloma.

Jacqueline Garcia: Evaluating Venetoclax Plus Azacitidine in Patients with High-Risk MDS

Dr. Jacqueline Garcia discusses evaluating venetoclax plus azacitidine in patients with high-risk MDS.

Tippi MacKenzie: In Utero Hematopoietic Cell Transplantation for Hematologic Conditions

Dr. Tippi MacKenzie discusses in utero hematopoietic cell transplantation for hematologic conditions.

Exploring Dosing Regimens of Sabatolimab Therapy for MDS/AML

Study findings support further exploration of specific dosing regimens of sabatolimab in patients with intermediate- to very high-risk MDS or AML.

Oncology Learning Network
New HOPE for Hemophilia B: One-Time Gene Therapy Abolishes Bleeding in Most Patients

A single dose of the gene therapy drug etranacogene dezaparvovec increased FIX activity levels, and eliminated the need for prophylactic FIX, in patients with severe to moderately severe hemophilia

Chemotherapy Plus Blinatumomab for Philadelphia Chromosome–Negative B-Cell ALL

This study showed that first-line treatment with a regimen of chemotherapy combined with the monoclonal antibody blinatumomab resulted in increased survival for patients who...

The ASCO Post
Early Signs of Risk for Myeloproliferative Neoplasms May Appear in Childhood or in Utero

Genetic mutations linked to myeloproliferative neoplasms may emerge in childhood or even in utero, decades before they cause cancer, according to a late-breaking abstract presented...

The ASCO Post
Safety & Clinical Activity of Combination Treatment for Multiple Myeloma

Belantamab mafodotin in combination with standard-of-care bortezomib/dexamethasone is safe for patients with R/R multiple myeloma who have received a median of three prior lines of therapy.

Oncology Times - Latest Articles
Study Finds Survival Disparities and Mutational Differences for Black Patients Younger Than 60 With AML

There is an urgent need to address this survival disparity in younger Black patients, as well as to conduct larger studies to establish molecular risk profiles of these patients, according...

The ASCO Post
High False-Negative RT-PCR Rates for SARS-CoV-2 Observed in Patients With Hematologic Malignancies

Hematologic malignancy was associated with more severe COVID-19 and high false-negative SARS-CoV-2 rates as measured by standard RT-PCR testing...

Cancer Therapy Advisor
Increased Mortality Rate Seen in Survivors of Thrombotic Thrombocytopenic Purpura

Survivors of TTP appear to have a 2-fold greater mortality rate compared with the general US population when adjusted for age, sex, and race, according to study findings presented...

Better EFS With Blinatumomab vs Chemo for High-Risk First Relapse of BCP-ALL

This study suggests blinatumomab monotherapy as a new standard-of-care consolidation therapy before allogeneic hematopoietic stem cell transplant in young patients with high-risk first-relapse BCP-

Oncology Learning Network
Multiple Myeloma Patient Similarity Network Identifies Prognostic Subgroups With Distinct Genetic and Clinical Features

An analysis by Bhalla et al of multiomics data from newly diagnosed patients with MM has identified 3 main patient groups and 12 prognostic subgroups based on five data types generated from...

The ASCO Post
ZUMA-5 Trial Finds Axicabtagene Ciloleucel Shows Activity in Patients With Indolent Non-Hodgkin Lymphoma

In the phase II ZUMA-5 trial, axicabtagene ciloleucel led to responses in 92% of patients with indolent non-Hodgkin lymphoma treated with the cellular immunotherapy. 

The ASCO Post
Novel Antibody-Drug Conjugate Shows Activity in Rare, Aggressive Form of Leukemia

A phase I/II study found that IMGN632, a novel CD123-targeting antibody-drug conjugate, was tolerable and resulted in a 29% overall response rate in patients with relapsed or refractory BPDCN. 

The ASCO Post
Long-Term Efficacy and Safety Demonstrated With Betibeglogene Autotemcel Gene Therapy in Transfusion-Dependent β-Thalassemia

An interim analysis of data from LTF-303 a 13-year follow-up study of patients with transfusion-dependent β-thalassemia who received beti-cel gene therapy, demonstrated durability...

Does Allogeneic HSCT Improve Outcomes in Older Patients with Myelodysplastic Syndrome Compared With Non-Transplantation Therapy?

Allogeneic HSCT should be offered to all patients with high-risk MDS who are aged 50 to 75 years and for whom a suitable donor can be identified...

BCMA-Directed CAR-T Therapy Shows Clinical Activity in Multiple Myeloma

An investigational CAR-T therapy that targets B-cell maturation antigen showed clinical activity in heavily pretreated patients with relapsed/refractory multiple myeloma...

Cancer Therapy Advisor
R-CHOP, Rituximab Maintenance Therapy Extend PFS in Patients With Newly Diagnosed FL

Rituximab maintenance therapy significantly prolonged PFS in patients with newly diagnosed FL given R-CHOP versus rituximab plus bendamustine...

Oncology Learning Network

source list reference